Diagnostic test for early detection of pancreatic cancer
| Reference number | |
| Coordinator | RECCAN AB (publ) |
| Funding from Vinnova | SEK 2 999 000 |
| Project duration | April 2024 - March 2026 |
| Status | Ongoing |
| Venture | Swelife - Collaboration project for better health |
| Call | Swelife - Collaborative projects for better health autumn 2023 |
Purpose and goal
** Denna text är maskinöversatt ** The purpose of Reccan´s project is to conduct clinical studies to collect data and insights about Reccan Immunoassay, a blood test for early detection of pancreatic cancer in at-risk patients. This is with the goal of being able to offer healthcare a simple test that can detect cancer at an early stage when it can be cured.
Expected effects and result
** Denna text är maskinöversatt ** The clinical activities planned in the project will provide data and insights that will support the inclusion of the test in treatment guidelines and to reach cost coverage for the test in healthcare in Europe. The overall goal is to increase survival for people with pancreatic cancer by offering a test that can detect the cancer at an early stage, which is currently lacking on the market.
Planned approach and implementation
** Denna text är maskinöversatt ** The project will be carried out together with an external CRO to produce the necessary documents and conduct the study.